Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

News Spotlights Stocks

BioNTech will likely take 900 million eur write-off on Pfizer-partnered vaccines

post-img

(Reuters) – Germany’s BioNTech (NASDAQ:BNTX) on Monday said it would likely take write-downs of up to 900 million euros ($947 million) in the third quarter after its partner Pfizer (NYSE:PFE) reported similar charges on their COVID-19 vaccine business last week.

Pfizer on Friday said it will take $900 million of inventory write-offs and other charges for the jointly developed vaccine, branded as Comirnaty, on top of much larger write-offs on Pfizer’s own COVID treatment Paxlovid.

BioNTech will likely “recognize the effect of Pfizer’s inventory write-offs and other charges related to Comirnaty in the third quarter of 2023 up to 0.9 billion euros, which represents BioNTech’s half of the gross profit-sharing agreement with Pfizer”, it said in a statement.

BioNTech, which is entitled to receive vaccine-related profit share payments from its U.S. partner, said the write-offs would also reduce its 2023 revenues.

A BioNTech spokesperson on Monday declined to comment on the company’s current outlook, which is for COVID-19 vaccine revenues of about 5 billion euros in 2023.

The company is scheduled to release detailed third-quarter figures on Nov. 6.

($1 = 0.9498 euros)

Related Post